GMED // Globus Medical Inc.

DES <GO> NYSE CIK 0001237831 ↗

Health Care • Medical/Dental Instruments

$82.91 ▲ +1.65 (+2.03%)

MKT CAP: $11.13B • VOL: 862.0K

52W L $60 52W H $101

ALTMAN Z

10.74 SAFE

PIOTROSKI

9 / 9

GMED // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

PRIOR: RQD 69/100 [C+] (-1 PT) • UNCHANGED AS OF 2026-11-01

ROARABLE C+

RQD CONFIDENCE

68 / 100 -1D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Hold — Upper Neutral / Watch for Breakout

01 MASSIVE / SEC XBRL

Forensic Fundamentals

16 / 20

STRONG

FCF +45.3% vs NI +200% • ROIC-WACC -1.3% • Z 10.74

02 OPRA GEX + SEC 13F

Whale & Options Flow

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

03 SEC FORM 4 (90D)

Insider Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

14 / 20

SOLID

TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00

05 10-K REDLINE AUDIT

Forensic 10-K Risk

16 / 20

STRONG

20 BASE - 4 DEDUCT • 0 CRIT / 0 MED • STABLE

ALERT

Why did GMED's Whale & Options Flow & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever GMED is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON GMED)

STAGE 2 DETERMINISTIC Z-SCORE + STAGE 3 GEEK DESK BRIEF ALL MARKET ANOMALIES <SIG>

▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS

SEVERITY: 85/100 Z-SCORE: +2.65σ

GMED Accounting Gap: Net Income (+220%) Outpaced OCF (+44.7%) With +-1.8% Working-Capital Build

CASH CONVERSION GAP

+175.3% (NI vs OCF)

RECEIVABLES / WC BLOAT

-1.8% VS REV

60D C-SUITE FORM 4 SALES

0 OPEN-MKT DUMPS

[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]

SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Globus Medical Inc. (GMED) exposes a +175.3% Cash Conversion Gap as YoY Net Income growth (+220.0%) diverged from Operating Cash Flow growth (+44.7%). Non-cash current assets and receivables expanded -1.8% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

GMED // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.45%📐 HORIZONTAL RANGE

2026-10-30O $80.80H $80.84L $77.77C $78.05VOL 1.68M

RES: $91.33SUP: $72.23SMA50: $77.62SMA200: $83.50

GMED // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

NEUTRAL / PAIR TRADE CONVICTION: 53/100

BEAR 0

100 BULL

Globus Medical Inc. (GMED) exhibits 67.4% gross margins and 8.7% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 17.6x enterprise multiple and 7.1% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 67.4% gross profitability converts into 16.3% operating margin and 8.7% ROIC, outpacing sector cost of capital.

ROIC: 8.7% // GM: 67.4%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +16.7% paired with 5.29% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +16.7% // FCF YLD: 5.29%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 10.74 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.

ALTMAN Z: 10.74 // F-SCORE: 9/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 20.7x trailing P/E (17.4x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 20.7x // EV/EBITDA: 17.6x

02. Options Skew & Event Volatility Risk

Options market prices a ±7.1% implied move with a 0.70 put/call ratio around $81.00 max pain.

IMPL MOVE: ±7.1% // P/C: 0.70

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 18.3% net margins.

NET MARGIN: 18.3% // D/E: 0.07x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 17.4x forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.07).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E 20.7x

FORWARD P/E 17.4x

EV / EBITDA 17.6x

FCF YIELD 5.29%

GROSS MARGIN 67.4%

OPERATING MARGIN 16.3%

NET MARGIN 18.3%

ROIC % 8.7%

REV GROWTH YOY +16.7%

DILUTED EPS TTM $4.01

DEBT / EQUITY 0.07x

DIVIDEND YIELD 0.00%

RSI-14 MOMENTUM 49.0

5Y EQUITY BETA 1.07

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // GMEDPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $75.87

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for GMED & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

GMED VS LLY

MARGINS ROIC VALUATION

GMED VS JNJ

MARGINS ROIC VALUATION

GMED VS ABBV

MARGINS ROIC VALUATION

GMED VS UNH

MARGINS ROIC VALUATION